Adlai Nortye Ltd. (ANL)
NASDAQ: ANL · Real-Time Price · USD
8.88
-0.04 (-0.39%)
Mar 9, 2026, 2:31 PM EDT - Market open
Adlai Nortye Employees
Adlai Nortye had 123 employees as of December 31, 2024. The number of employees decreased by 4 or -3.15% compared to the previous year.
Employees
123
Change (1Y)
-4
Growth (1Y)
-3.15%
Revenue / Employee
n/a
Profits / Employee
-$346,276
Market Cap
327.49M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 123 | -4 | -3.15% |
| Dec 31, 2023 | 127 | -2 | -1.55% |
| Dec 31, 2022 | 129 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| X4 Pharmaceuticals | 143 |
| Foghorn Therapeutics | 112 |
| Neurogene | 107 |
| Rezolute | 75 |
| Immuneering | 54 |
| Protara Therapeutics | 33 |
| Avalo Therapeutics | 23 |
| Opus Genetics | 18 |
ANL News
- 25 days ago - Adlai Nortye Announces First Patient Enrolled in Global Phase 1 Trial of Pan-RAS (ON) Inhibitor AN9025 for Solid Tumors Harboring RAS Mutations - GlobeNewsWire
- 4 weeks ago - Adlai Nortye Announces $140.0 Million Private Placement Equity Financing - GlobeNewsWire
- 2 months ago - Adlai Nortye Enters Exclusive License Agreement with ASK Pharm for Pan-RAS (ON) Inhibitor AN9025 in Greater China - GlobeNewsWire
- 5 months ago - Adlai Nortye to Present Short Talk at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - GlobeNewsWire
- 1 year ago - Adlai Nortye Ltd. to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy (dCRT) at ASCO 2024 - GlobeNewsWire
- 1 year ago - Adlai Nortye Announces First Patient Dosed in Randomized Phase II Clinical Trial of Palupiprant (AN0025) for the Treatment of Locally Advanced Rectal Cancer with Radiation Therapy - GlobeNewsWire
- 2 years ago - Adlai Nortye Announces Appointment of Dr. Archie Tse as the Head of Research & Development - GlobeNewsWire
- 2 years ago - Adlai Nortye Announces Completion of Patient Enrollment in Global Phase III Clinical Trial of Buparlisib (AN2025) in Combination with Paclitaxel for the Treatment of Recurrent or Metastatic HNSCC - GlobeNewsWire